Article Sidebar
Published:
Jan 11, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
<i>In vivo</i> and <i>in silico</i> investigation of selected herbal compounds as anti-tubercular agents
Abstract
Purpose: To investigate whether some herbal compounds, namely, arctiin, NSC333050, cnicin, and arctigenin, can be used as anti-tubercular agents using in vivo and in silico techniques.
Methods: A set of structurally diverse herbal compounds were screened for anti-tubercular activity against the Mycobacterium tuberculosis (Mtb) H37v strain by determining their microbial inhibitory concentration (MIC) and cytotoxicity. The compounds were also screened using in silico techniques, such as molecular docking and absorption, distribution, metabolism, and excretion (ADME) prediction.
Results: The in vivo methods, such as determination of MIC and cytotoxicity assay, revealed that some of the herbal compounds showed superior anti-tubercular activity. In silico approaches involving molecular docking simulations for the mycobacterial enzymes Mtb DNA gyrase, Mtb betalactamase, Mtb diaminopelargonic acid synthase, and Mtb cytidine 5'-triphosphate synthase (CTP) confirmed that the inhibitory activities of the herbal compounds occurred at the active sites of these enzyme. In silico ADME prediction also confirmed the pharmacokinetic safety of these herbal compounds.
Conclusion: Arctiin, NSC333050, cnicin, and arctigenin, are suitable candidates for clinical evaluation for the treatment of respiratory infections caused by Mtb.
Keywords: Tuberculosis, Microbial inhibitory concentration, Arctiin, Cnicin, Arctigenin, In silico, Respiratory infection
